腹水细胞块诊断原发性卵巢、腹膜和输卵管癌的效能
该回顾性研究纳入81例伴腹水的腹膜癌病女性患者,以腹膜肿瘤空心针活检(CNB)为参考标准,比较腹水细胞块(ACB)与CA125/CEA比值诊断原发性输卵管卵巢癌的效能。结果显示ACB不劣于CNB且两者互补,ACB优于CA125/CEA比值>25。
要点
- ACB诊断原发性输卵管卵巢癌不劣于CNB,两者可互补。
- ACB免疫组化与CNB的一致率为93.6%。
- ACB诊断效能优于CA125/CEA比值>25。
核心结论
- ACB诊断原发性输卵管卵巢癌不劣于CNB,两者互补,可在特定患者中替代CNB。
- ACB诊断原发性输卵管卵巢癌优于CA125/CEA比值>25。
研究设计与样本
- 回顾性研究,纳入81例伴腹水的腹膜癌病女性患者,均具备ACB、腹膜肿瘤CNB及CA125/CEA比值结果。
- 以CNB为参考标准,计算并比较ACB与CA125/CEA比值的诊断效能。
主要发现
- 81例中57例临床诊断为原发性输卵管卵巢癌。
- CNB、ACB和CA125/CEA比值>25分别诊断52例、47例和64例。
- CNB和ACB分别识别癌症来源的91.4%和82.7%病例。
- ACB与CNB的免疫组化结果一致率为93.6%。
- 2例CNB结果不确定的患者经ACB诊断为原发性输卵管卵巢癌。
关键数值与推荐
- ACB灵敏度86.5%、特异度93.1%、阳性预测值95.7%、阴性预测值79.4%、阳性似然比12.5。
- CA125/CEA比值>25灵敏度94.2%、特异度48.3%、阳性预测值76.6%、阴性预测值82.4%、阳性似然比1.82。
临床怎么用
- 在伴腹水的腹膜癌病患者中,ACB可有效、可靠且便捷地诊断原发性输卵管卵巢癌。
- ACB可在特定患者中替代CNB,并与CNB互补使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of ascitic fluid cell block (ACB) with that of core needle biopsy (CNB) or the CA125/CEA ratio in diagnosing primary tubo-ovarian cancer in female patients with peritoneal carcinomatosis (PC) with ascites. METHODS: This retrospective study examined female patients with PC with ascites who had available results for ACB, peritoneal tumor CNB, and the CA125/CEA ratio. Several measures of the accuracy of ACB and the CA125/CEA ratio were calculated and compared, with CNB as the reference standard. RESULTS: Of 81 patients with available results, 57 were clinically diagnosed with primary tubo-ovarian cancer. Overall, 52, 47, and 64 patients were diagnosed via CNB, ACB, and CA125/CEA ratio > 25, respectively. CNB and ACB identified the cancer origin in 91.4% and 82.7% cases, respectively. The concordance ratio of the immunohistochemical findings between ACB and CNB was 93.6%. Two patients with inconclusive CNB results were diagnosed with primary tubo-ovarian cancer via ACB. The sensitivity, specificity, positive predictive value, negative predictive value, and positive likelihood ratio were 86.5%, 93.1%, 95.7%, 79.4%, and 12.5, respectively, for ACB and 94.2%, 48.3%, 76.6%, 82.4%, and 1.82, respectively, for CA125/CEA ratio > 25. CONCLUSIONS: ACB is not inferior to CNB in diagnosing primary tubo-ovarian cancer; the two methods complement each other. ACB can substitute CNB in diagnosing primary tubo-ovarian cancer in selected PC patients. ACB is superior to a CA125/CEA ratio of >25 in diagnosing primary tubo-ovarian cancer. ACB is effective, reliable, and convenient for diagnosing primary tubo-ovarian cancer in PC patients with ascites.
引用
- Uehara T, Yoshida H, Fukuhara M, et al. Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites. Gynecol Oncol. 2020. PMID: 32063274. doi:10.1016/j.ygyno.2020.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。